S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
NASDAQ:ALBO

Albireo Pharma - ALBO Stock Forecast, Price & News

$44.07
+0.12 (+0.27%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$43.82
$44.08
50-Day Range
$18.01
$44.10
52-Week Range
$16.02
$44.40
Volume
846,186 shs
Average Volume
719,190 shs
Market Capitalization
$912.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.00

Albireo Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
8.9% Upside
$48.00 Price Target
Short Interest
Healthy
3.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.69
Upright™ Environmental Score
News Sentiment
0.36mentions of Albireo Pharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$178,670 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.86) to ($6.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

492nd out of 1,055 stocks

Pharmaceutical Preparations Industry

239th out of 519 stocks


ALBO stock logo

About Albireo Pharma (NASDAQ:ALBO) Stock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Stock News Headlines

ALBO.PH - | Stock Price & Latest News | Reuters
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Albireo Pharma, Inc. (NASDAQ:ALBO) Short Interest Update
Why These Two Biotech Stocks Blasted Higher This Week
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Expert Ratings for Albireo Pharma
Albireo Announces 2022 SPARK Grant Winners
See More Headlines
Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Company Calendar

Last Earnings
11/08/2022
Today
1/28/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALBO
Employees
130
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$48.00
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+8.9%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-34,030,000.00
Net Margins
-228.51%
Pretax Margin
-235.11%

Debt

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$9.11 per share

Miscellaneous

Free Float
19,273,000
Market Cap
$912.25 million
Optionable
Optionable
Beta
0.81

Social Links


Key Executives

  • Mr. Ronald H. W. Cooper (Age 60)
    CEO, Pres & Director
    Comp: $1.1M
  • Mr. Simon Nicolas Reade Harford (Age 62)
    CFO & Treasurer
    Comp: $687.78k
  • Ms. Martha J. Carter (Age 71)
    Chief Regulatory Officer
    Comp: $710.69k
  • Dr. Per-Goran Gillberg Ph.D.
    Co-Founder & VP of Devel.
  • Dr. Jan P. Mattsson Ph.D. (Age 59)
    Chief Scientific Officer, MD (Sweden) & Co-Founder
  • Ms. Joan Connolly
    Chief Technology Officer
  • Mr. Jason G. DuncanMr. Jason G. Duncan (Age 49)
    Chief Legal Officer, Gen. Counsel & Sec.
  • Ms. Michelle Graham (Age 56)
    Chief HR Officer
  • Dr. Kristina Torfgard
    VP & Global Project Head
  • Ms. Pamela  Stephenson M.P.H.Ms. Pamela Stephenson M.P.H. (Age 55)
    Chief Commercial Officer













ALBO Stock - Frequently Asked Questions

Should I buy or sell Albireo Pharma stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALBO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALBO, but not buy additional shares or sell existing shares.
View ALBO analyst ratings
or view top-rated stocks.

What is Albireo Pharma's stock price forecast for 2023?

7 equities research analysts have issued twelve-month target prices for Albireo Pharma's stock. Their ALBO share price forecasts range from $42.00 to $59.00. On average, they anticipate the company's share price to reach $48.00 in the next year. This suggests a possible upside of 8.9% from the stock's current price.
View analysts price targets for ALBO
or view top-rated stocks among Wall Street analysts.

How have ALBO shares performed in 2023?

Albireo Pharma's stock was trading at $21.61 at the start of the year. Since then, ALBO shares have increased by 103.9% and is now trading at $44.07.
View the best growth stocks for 2023 here
.

When is Albireo Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ALBO earnings forecast
.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($1.89) EPS for the quarter, missing analysts' consensus estimates of ($1.86) by $0.03. The biopharmaceutical company had revenue of $9.83 million for the quarter, compared to the consensus estimate of $9.68 million. Albireo Pharma had a negative net margin of 228.51% and a negative trailing twelve-month return on equity of 97.13%.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Chicago Capital LLC (6.58%) and Rice Hall James & Associates LLC (2.48%). Insiders that own company stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends
.

How do I buy shares of Albireo Pharma?

Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $44.07.

How much money does Albireo Pharma make?

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $912.29 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis.

How many employees does Albireo Pharma have?

The company employs 130 workers across the globe.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.

This page (NASDAQ:ALBO) was last updated on 1/28/2023 by MarketBeat.com Staff